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The existing biopharmaceutical manufacturing paradigm is poorly suited to produce biologic drugs on demand at 
a point-of-care.  Generally, commercial-scale (~2,000 - 10,000 L) manufacturing using fed-batch cultivation and 
fixed stainless-steel infrastructure is concentrated in developed nations and results in process cycle times on the 
order of weeks to months.1,2  Coupled with the complex logistical challenges associated with continuous “plant-
to-patient” cold-chains, the geographically biased nature of therapeutic protein production today can limit access 
to biologic drugs in developing areas of the world.3  There is an opportunity to create technologies capable of 
rapidly generating biopharmaceuticals in situ in emergency situations, in remote healthcare settings, and in the 
battlefield.  A platform that incorporates a modular suite of bioreactor, purification, and in-line analytics 
technologies has the potential to bridge this gap if developed in parallel with appropriately engineered stains of a 
flexible expression host.  This poster will describe a multifaceted approach towards the development of a fully 
automated bench-scale perfusion process for the cultivation of Pichia pastoris and expression of therapeutically 
relevant heterologous proteins.  We demonstrate the application of computational fluid dynamics (CFD) 
simulations to the optimization of the cultivation environment within our bench-top bioreactors.  We further show 
that Pichia pastoris is amenable to secreting a variety of recombinant proteins spanning a range of preexisting 
drug classes (e.g. hormones, cytokines, monoclonal antibodies, vaccine antigens).  Among these therapeutic 
proteins are molecules that require proper co-/post-translational processing for bioactivity.  We envision that the 
development of P. pastoris strains with the capability to perform these critical processing steps in vivo will mitigate 
the need to chemically modify proteins post-expression and reduce the number of unit operations required in a 
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